Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients

Tiago Torres, Margarida Gonçalo, Maria João Paiva Lopes, Cristina Claro, Leonor Ramos, Manuela Selores, Pedro Mendes Bastos, Joana Rocha, Rodrigo Carvalho, Alberto Mota, Paulo Filipe on Behalf of the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology

Article Type

Recommendation

Published

This article presents recommendations developed by the Atopic Dermatitis Group of the Portuguese Society of Dermatology and Venereology addressing several clinical questions that arise in the management and care of moderate-tosevere atopic dermatitis with biologic agents and Janus kinase inhibitors based on the available evidence.

Read more

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib

Novin Nezamololama, BSc, MSc, Keira Fieldhouse, BSc, Kristy Metzger, BSc, Melinda Gooderham, MD, MSc, FRCPC

Article Type

Review

Published

This review summarizes the clinical data available from various trials and reports on the safety and efficacy of abrocitinib, baricitinib, and upadacitinib, the three oral systemic JAK inhibitors used in the treatment of atopic dermatitis.

Read more

Conjunctivitis in patients with atopic dermatitis treated with dupilumab

Sandra Ferreira MD, Tiago Torres MD, PhD

Article Type

Review

Published

The present paper reviews the data of dupilumab-associated conjunctivitis and risk factors in adults with moderate-to-severe AD and other atopic diseases in dupilumab clinical trials and addresses the characteristics and treatment options available for this clinically highly relevant condition.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.